Simplify Logo

Full-Time

Principal Scientist

Protein Analytics & Biophysics-Target Binding

Confirmed live in the last 24 hours

Generate Biomedicines

Generate Biomedicines

51-200 employees

Generates novel medicines using machine learning

AI & Machine Learning
Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • PhD in a scientific field of study and 8+ years of relevant research experience, Master’s degree in a scientific field of study and 14 years of relevant research experience, or B.S. in a science-related discipline with 16+ years of relevant research experience. Industry experience is required
  • Deep expertise and extensive hands-on experience in biomolecular interaction analysis using biosensor-based platforms (Carterra LSA, Biacore, Octet) and solution-based approaches (KinExA, Gyrolab) is required
  • Highly skilled in experimental design with a strong ability to analyze, interpret and communicate complex kinetic and mechanistic data
Responsibilities
  • Drive the design and execution of fit-for-purpose binding assays and workflows using techniques such as surface plasmon resonance (SPR), bio-layer interferometry (BLI) and kinetic exclusion assay (KinExA) in alignment with program goals and with broader organizational objectives
  • Demonstrate a proven track record of efficiently collating, analyzing, visualizing, interpreting and communicating complex data sets using a repertoire of digital tools
  • Pioneer efforts to maximize productivity, streamline processes and expand machine learning capabilities by integrating new and innovative technologies
  • Collaborate with computational scientists and multidisciplinary project teams to support critical decision-making checkpoints throughout discovery process
  • Provide technical oversight and strategic guidance to functional team members
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines focuses on creating new medicines using a method called generative biology, which combines machine learning and biological engineering. This approach involves analyzing millions of proteins to learn how nature encodes their functions, allowing the company to design new medicines with specific therapeutic effects. The main product, The Generate Platform, enables the rapid production of medicines across various therapeutic areas, significantly improving the drug discovery process compared to traditional methods. Unlike its competitors, Generate Biomedicines emphasizes a proactive and efficient approach to medicine creation, aiming to democratize access to biotherapeutics. The company's goal is to expand its capabilities in generating and testing proteins, having already produced 42,000 proteins, and to continue advancing the field of therapeutics.

Company Stage

Series C

Total Funding

$693M

Headquarters

Somerville, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

5%

1 year growth

15%

2 year growth

44%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $273M Series C financing round provides substantial capital to advance their generative AI pipeline and clinical programs.
  • Expansion of the leadership team with experienced professionals like Rupert Vessey, Nancy Simonian, and Kym White strengthens the company's strategic direction and operational capabilities.
  • Publication of the Chroma model in Nature highlights the company's innovative contributions to protein therapeutics, enhancing its reputation in the scientific community.

What critics are saying

  • The reliance on cutting-edge generative AI and machine learning technologies may face regulatory and adoption challenges in the conservative pharmaceutical industry.
  • Rapid expansion and scaling efforts, including new hires and leadership changes, could lead to integration and cultural challenges.

What makes Generate Biomedicines unique

  • Generate Biomedicines leverages generative biology and machine learning to create medicines on demand, a significant departure from traditional drug discovery methods.
  • The Generate Platform's ability to produce novel medicines across multiple therapeutic areas with high speed and success rates sets it apart from competitors.
  • Their focus on understanding the rules by which nature encodes function to design new proteins is a unique approach in the biotechnology sector.